35,900 Shares in Organogenesis Holdings Inc. (NASDAQ:ORGO) Acquired by Bailard Inc.

Bailard Inc. acquired a new position in shares of Organogenesis Holdings Inc. (NASDAQ:ORGO) in the 4th quarter, HoldingsChannel reports. The fund acquired 35,900 shares of the company’s stock, valued at approximately $147,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. SG Americas Securities LLC acquired a new stake in Organogenesis during the 3rd quarter worth $92,000. Bank of New York Mellon Corp increased its position in shares of Organogenesis by 1.5% during the third quarter. Bank of New York Mellon Corp now owns 495,729 shares of the company’s stock worth $1,576,000 after purchasing an additional 7,432 shares in the last quarter. Principal Financial Group Inc. purchased a new stake in shares of Organogenesis in the 3rd quarter valued at about $32,000. Arizona State Retirement System acquired a new stake in shares of Organogenesis in the 3rd quarter valued at about $65,000. Finally, Barclays PLC grew its stake in Organogenesis by 80.6% during the 3rd quarter. Barclays PLC now owns 25,276 shares of the company’s stock worth $80,000 after buying an additional 11,284 shares during the last quarter. 49.57% of the stock is owned by institutional investors and hedge funds.

Organogenesis Stock Performance

Shares of ORGO stock opened at $2.46 on Tuesday. The stock has a market capitalization of $323.96 million, a PE ratio of 61.39 and a beta of 1.57. The company has a quick ratio of 2.44, a current ratio of 2.80 and a debt-to-equity ratio of 0.22. The stock’s 50-day moving average price is $2.92 and its 200 day moving average price is $3.09. Organogenesis Holdings Inc. has a 52-week low of $1.88 and a 52-week high of $4.70.

Wall Street Analysts Forecast Growth

Separately, Cantor Fitzgerald reiterated an “overweight” rating and issued a $5.00 price objective on shares of Organogenesis in a research note on Friday, March 1st.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.